Goldman Sachs Starts WuXi PharmaTech (WX) at Buy, Adds to Conviction Buy List

Goldman Sachs initiates coverage on WuXi PharmaTech Inc. (NYSE: WX) with a Buy rating and $15.63 price target and added the stock to their Conviction Buy List.

The firm sees earnings CAGR of 28% for 2009E-2011E and expects WuXi to register above-peer-average operating and net margins of 20% and 17% in 2011E.

Catalysts the analyst cited included: scale, attractive outsourcing location, and business model.

Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
• When Will Rosetta Genomics (ROSG) Crash From its 1346% Gain?
• Vodafone (VOD) Volatility Pops Early, Shares Inch Higher

Create E-mail Alert Related Categories

New Coverage, Trader Talk

Related Entities

Goldman Sachs Conviction Buy List

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter